[Novel antithrombotic drugs. From the 19th Congress of the International Society on Thrombosis and Haemostasis].
E V
EV
Pokrovskaia
D000328:Adult; D000367:Age Factors; D000368:Aged; D000925:Anticoagulants; D001384:Azetidines / Q000008:administration & dosage / Q000627:therapeutic use; D001596:Benzylamines; D017985:Dalteparin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000077425:Fondaparinux; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009844:Oligosaccharides / Q000008:administration & dosage / Q000627:therapeutic use; D010919:Placebos; D011134:Polysaccharides / Q000008:administration & dosage / Q000627:therapeutic use; D011355:Prodrugs; D011655:Pulmonary Embolism / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D013923:Thromboembolism / Q000188:drug therapy / Q000517:prevention & control; D018180:Thrombomodulin / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D005343:Fibrinolytic Agents; D009844:Oligosaccharides; D010919:Placebos; D011134:Polysaccharides; D011355:Prodrugs; D018180:Thrombomodulin; C426686:ximelagatran; D014859:Warfarin; C479958:idraparinux; D000077425:Fondaparinux; D017985:Dalteparin